Rasagiline: Neurodegeneration neuroprotection, and mitochondrial permeability transition

Journal of Neuroscience Research

Volumn 79, Issue 1-2, 2005, Pages 172-179

  Youdim, Moussa B H ^a   Am, Orit Bar ^a   Yogev Falach, Merav ^a   Weinreb, Orly ^a   Maruyama, Wakako ^b   Naoi, Makato ^b   Amit, Tamar ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

Author keywords

Bcl 2 family members; Caspase 3; Propargyl moiety; Protein kinase C; Rasagiline; SHSY5Y neuroblastoma cells

Indexed keywords

ALPHA SECRETASE; AMPHETAMINE; AMYLOID PRECURSOR PROTEIN; ANTIPARKINSON AGENT; CASPASE 3; CHOLINESTERASE; FAS ANTIGEN; LADOSTIGIL; LEVODOPA; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE B INHIBITOR; NEUROTOXIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG;

ANOXIA; BRAIN ISCHEMIA; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; HEAD INJURY; HUMAN; ISOMER; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM INJURY; NEUROPROTECTION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; CHOLINESTERASE INHIBITORS; GENOMICS; HUMANS; INDANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARGYLINE; PERMEABILITY; PROPYLAMINES; PROTEIN KINASE C; PROTEOMICS;

EID: 12244296145     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20350     Document Type: Conference Paper

References (77)

1. Adams JM, Cory S. 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326.
2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MBH, Naoi M. 2002a. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326:105-108.
3. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M. 2002b. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82:913-923.
4. Bar-Am OB, Amit T, Youdim MB. 2004a. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169-172.
5. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB. 2004b. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 89:1119-1125.
6. Belzacq AS, Brenner C. 2003. The adenine nucleotide translocator: a new potential chemotherapeutic target. Curr Drug Targets 7:517-524.
7. Belzacq AS, Vieira HL, Kroemer G, Brenner C. 2002. The adenine nucleotide translocator in apoptosis. Biochimie 84:167-176.
8. Belzacq AS, Vieira HL, Verrier F, Vandecasteele G, Cohen I, Prevost MC, Larquet E, Pariselli F, Petit PX, Kahn A, Rizzuto R, Brenner C, Kroemer G. 2003. Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res 63:541-546.
9. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. 2004. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 187:455-459.
10. Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P. 1990. Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 87:6003-6006.
11. Caputi A, Barindelli S, Pastorino L, Cimino M, Buxbaum JD, Cattabeni F, Di Luca M. 1997. Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive upregulation of protein kinase C. J Neurochem 68:2523-2529.
12. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MB. 2000. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67:577-585.
13. Cory S, Adams JM. 2002. The Bcl2 family: regulator of the cellular life-or-death switch. Nat Rev Cancer 2:647-656.
14. Durkin JP, Tremblay R, Chakravarthy B, Mealing G, Morley P, Small D, Song D. 1997. Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons. J Neurochem 68:1400-1412.
15. Evan G, Littlewood T. 1998. A matter of life and cell death. Science 28:1317-1322.
16. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. 1998. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9:703-707.
17. Finberg JP, Youdim MB, 2002. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43:1110-1118.
18. Halestrap AP, McStay GP, Clarke SJ. 2002. The permeability transition pore complex: another view. Biochimie 84:153-166.
19. Hama T, Huang KP, Guroff G. 1986. Protein kinase C as a component of a nerve growth factor-sensitive phosphorylation system in PC12 cells. Proc Natl Acad Sci USA 83:2353-2357.
20. Hsieh YC, Jao HC, Yang RC, Hsu HK, Hsu C. 2003. Suppression of protein kinase Calpha triggers apoptosis through down-regulation of Bcl-xL in a rat hepatic epithelial cell line. Shock 19:582-587.
21. Huang W, Chen Y, Shohami E, Weinstock M. 1999. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 366:127-135.
22. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230-232.
23. Jellinger KA. 2000. Cell death mechanisms in Parkinson's disease. J Neural Transm 107:1-29.
24. Jin LW, Saitoh T. 1995. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. Drugs Aging 6:136-149.
25. Katsura K, Kurihara J, Hiraide T, Takahashi K, Kato H, Katayama Y. 2003. Effects of FK506 on the translocation of protein kinase C and CaM kinase II in the gerbil hippocampal CA1 neurons. Neurol Res 25:522-527.
26. Kribben A, Wieder ED, Li X, van Putten V, Granot Y, Schrier RW, Nemenoff RA. 1993. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am J Physiol 265:939-945.
27. Lin L, Georgievska B, Mattsson A, Isacson O. 1999. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci USA 96:12108-12113.
28. Maher P. 2001. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J Neurosci 21:2929-2938.
29. Maruyama W, Akao Y, Youdim MB, Naoi M. 2000. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl 60:171-186.
30. Maruyama W, Akao Y, Youdim MB, Boulton AA, Davis BA, Naoi M. 2001b. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727-735.
31. Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M. 2001a. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J Neural Transm 108:11-24.
32. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Yodim M, Furukawa S, Nabeshima T, Naoi M. 2004. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44:393-400.
33. Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M. 2003. Antiapoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 8:233-236.
34. Maruyama W, Youdim MB, Naoi M. 2001c. Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. Ann N Y Acad Sci 939:320-329.
35. Masliah E, Cole GM, Hansen LA, Mallory M, Albright T, Terry RD, Saitoh T. 1991. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J Neurosci 11:2759-2767.
36. Matsushima H, Shimohama S, Chachin M, Taniguchi T, Kimura J. 1996. Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease. J Neurochem 67:317-323.
37. Middleton, G, Wyatt S, Nikiman N, Davies M, Nabeshima T. 2001. Reciprocal developmental changes in the roles of Bcl-w and Bcl-x(L) in regulating sensory neuron survival. Development 128:447-457.
38. Montz HP, Davis GE, Skaper SD, Manthorpe M, Varon S. 1985. Tumor-promoting phorbol diester mimics two distinct neurotrophic factors. Brain Res 355:150-154.
39. Murer MG, Yan Q, Raisman-Vozari R. 2001. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63:71-124.
40. Naoi M, Maruyama W, 2001. Future of neuroprotection in Parkinson's disease. Parkinsonism Relat Disord 8:139-145.
41. Nishizuka Y. 1988. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334:661-665.
42. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307.
43. Oltvai ZN, Milliman CL, Korsmeyer SJ. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619.
44. Parain K, Murer MG, Yan O, Faucheux B, Agid Y, Hirsch E, Raisman Vozari R. 1999. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10:557-561.
45. Parkinson Study Group. 2002. A controlled trial of rasagiline in early Parkinson disease. Arch Neurol 59:1937-1993.
46. Parkinson Study Group. 2004. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561-566.
47. Rossner S, Ueberham U, Yu J, Kirazov L, Schliebs R, Perez-Polo JR, Bigl V. 1997. In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity. Eur Neurosci 9:2125-2134.
48. Roth GS, Joseph JA, Mason RP. 1995. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 18:203-206.
49. Ruvolo PP, Deng X, Carr BK, May WS. 1998. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273:25436-25442.
50. Sagi Y, Weinreb O, Weinstock M, Youdim MB. 2001. Neuroprotective and neurorescue properties of rasagiline and TV3326 in MPTP model of Parkinson's disease. Neural Plast 8:197-198.
51. Sagi Y, Weinstock M, Youdim MB. 2003. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 85:290-297.
52. Schmittgen TD, Zakrajsek BA. 2000. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 46:69-81.
53. Selvatici R, Marino S, Piubello C, Radi D, Beani C, Gardini E, Siniscalchi A. 2003. Protein kinase C activity, translocation, and selective isoform subcellular redistribution in the rat cerebral cortex after in vitro ischemia. J Neurosci Res 71:64-71.
54. Shimohama S, Narita M, Matsushima H, Kimura J, Kameyama M, Hagiwara M, Hidaka H, Taniguchi T. 1993. Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. Neurology 43:1407-1413.
55. Slack BE, Nitsch RM, Livneh E, Kunz GM Jr, Breu J, Eldar H, Wurtman RJ. 1993. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts over expressing protein kinase C alpha. J Biol Chem 268:21097-21101.
56. Tsujimoto Y, Shimizu S. 2000. Bcl-2 family: life-or-death switch. FEBS Lett 466:6-10.
57. Speiser Z, Mayk A, Eliash S, Cohen S. 1999. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 106:593-606.
58. Suleiman MS, Halestrap AP, Griffiths EJ. 2001. Mitochondria: a target for myocardial protection. Pharmacol Ther 89:29-46.
59. Tan Y, Ruan HD, Comb MJ. 1999. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem 274:34859-34867.
60. Tremblay R, Hewitt K, Lesiuk H, Mealing G, Morley P, Durkin JP. 1999. Evidence that brain-derived neurotrophic factor neuroprotection is linked to its ability to reverse the NMDA-induced inactivation of protein kinase C in cortical neurons. J Neurochem 72:102-111.
61. Vianna MR, Barros DM, Silva T, Choi H, Madche C, Rodrigues C, Medina JH, Izquierdo I. 2000. Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats. Psychopharmacology 150:77-84.
62. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. 2004. Rasagiline alone and in combination with rituzole prolongs survival in ALS mouse model. J Neurol 251:1080-1084.
63. Wang HY, Pisano MR, Friedman E. 1994. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. Neurobiol Aging 15:293-298.
64. Weinreb O, Bar-Am O, Amit T, Youdim MB. 2004. Neuroprotection via Bcl-2 PKC interaction. FSAEB J 18:1471-1473.
65. Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg J, Youdim MB. 2000. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm Suppl 60:157-170.
66. Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MB, Shoham S. 2001. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci 939:148-161.
67. Weinstock M, Poltyrev T, Bejar C, Youdim MB. 2002. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) 160:318-324.
68. Weinstock M, Poltyrev T, Gross A, Sagi Y, Youdim MB. 2003. A novel cholinesterase and brain selective monamine oxidase inhibitor for treatment of dementia co-morbid with depression and parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 27:555-561.
69. Yogev-Falach M, Amit T, Bar-Am O, Sagi Y, Weinstock M, Youdim MB. 2002. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16:1674-1676.
70. Yogev-Falach M, Amit T, Bar-Am O, Youdim MB. 2003. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J 17:2325-2327.
71. Youdim MB. 2003. Rasagiline; an anti-Parkinson drug with neuroprotective activity. Exp Rev Neurotherapeutics 3:737-749.
72. Youdim MB, Amit T, Yogev-Falach M, Bar-Am O, Maruyama W, Naoi M. 2003. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol 66:1635-1641.
73. Youdim MB, Gross A, Finberg JP. 2001a. Rasagiline [N-propargyl-1R(+) aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500-506.
74. Youdim MB, Wadia A, Tatton W, Weinstock M. 2001b. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939:450-458.
75. Youdim MB, Weinstock M. 2001. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol 21:555-573.
76. Yuan J, Yankner BA. 2000. Apoptosis in the nervous system. Nature 407:802-809.
77. Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G. 1998. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16:2265-2282.